• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Pacific Biosciences of California Inc.

    11/14/24 5:52:54 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $PACB alert in real time by email
    SC 13G 1 ss4037903_sc13g.htm SCHEDULE 13G

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     



     

    Pacific Biosciences of California, Inc.
    (Name of Issuer)

     

     

    Common Stock
    (Title of Class of Securities)

     

    69404D108

     
    (CUSIP Number)

     

    September 30, 2024

     
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

      



      

      

     

     
             
    1

    NAME OF REPORTING PERSONS

     EDMOND DE ROTHSCHILD ASSET MANAGEMENT (FRANCE)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

     
    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    France

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    18,805,980

    7

    SOLE DISPOSITIVE POWER

     

    1,501,900

    8

    SHARED DISPOSITIVE POWER

     18,805,980

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    20,307,880

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.5%

    12

    TYPE OF REPORTING PERSON

     FI

     

     

     

     

     

     

     

     

     

     

      

     

     

     

             
    1

    NAME OF REPORTING PERSONS

     EDMOND DE ROTHSCHILD ASSET MANAGEMENT (LUXEMBOURG)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

     
    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    14,995,980

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     14,995,980

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    14,995,980

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.5%

    12

    TYPE OF REPORTING PERSON

     FI

     

     

     

     

     

     

      

     

     

             
    1

    NAME OF REPORTING PERSONS

     EDMOND DE ROTHSCHILD FUND

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

     
    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    14,862,300

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     14,862,300

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    14,862,300

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.5%

    12

    TYPE OF REPORTING PERSON

     FI

     

     

     

     

     

     

      

     

     

     

    Item 1.   (a) Name of Issuer:
        Pacific Biosciences of California, Inc.

     

        (b) Address of Issuer’s Principal Executive Offices:

    1305 O’Brien Drive

    Menlo Park, California 94025

    Item 2.   (a) Name of Person Filing:

    This Schedule 13G is being filed on behalf of each of the following persons (each, a “Reporting Person”) :

    1.EDMOND DE ROTHSCHILD ASSET MANAGEMENT (FRANCE) (“EDRAM France”)
    2.EDMOND DE ROTHSCHILD ASSET MANAGEMENT (LUXEMBOURG) (“EDRAM Luxembourg”)

     3.EDMOND DE ROTHSCHILD FUND (“EdR Fund”)

     

        (b) Address of Principal Business Office:

    The address of EDRAM France is 47, RUE DU FAUBOURG SAINT HONORE PARIS, FRANCE 75008.

    The address of EDRAM Luxembourg is 4, RUE ROBERT STUMPER, LUXEMBOURG L-2557.

    The address of EdR Fund is 4, RUE ROBERT STUMPER, LUXEMBOURG L-2557.

        (c) Citizenship:

    EDRAM France is a French entity

    EDRAM Luxembourg is a Luxembourg entity

    EdR Fund is a société d’investissement à capital variable (SICAV) Luxembourg formed under the laws of Luxembourg.

        (d) Title of Class of Securities:

    Common Stock

        (e) CUSIP No.:

             69404D108

     

    Item 3.      

    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J)

     

    Item 4. Ownership:

    Ownership as of September 30, 2024 is incorporated by reference to items (5) – (9) and (11) of the cover page of each Reporting Person. Both EDRAM France and EDRAM Luxembourg, management companies, may be deemed to have beneficial ownership of the securities which are the subject of this filing through the investment and/or voting discretion it exercises over its portfolios managed. Besides, EdR Fund, a société d’investissement à capital variable (SICAV) formed under the laws of Luxembourg, is the beneficial owner of more than 5% of the outstanding securities identified on this Schedule 13G.

    Item 5. Ownership of Five Percent or Less of a Class.

    Not Applicable

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

    Not Applicable

     

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable

     

      

     

    Item 8. Identification and Classification of Members of the Group.

     Not Applicable

     

     

    Item 9. Notice of Dissolution of Group.

     Not Applicable

     

     

    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory schemes applicable to the Reporting Persons are substantially comparable to the regulatory schemes applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

      

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:  November 14, 2024

     

     

    EDMOND DE ROTHSCHILD ASSET MANAGEMENT (FRANCE)

     

    By: /s/ Benjamin Melman

    Name: Benjamin Melman

    Title: Global Chief Investment Officer

       
       
     

    EDMOND DE ROTHSCHILD ASSET MANAGEMENT (LUXEMBOURG)

     

    By: /s/ Enrique Bouillot

    Name: Enrique Bouillot

    Title: COMEX Member

     

    By: /s/ Emmanuel Vergeynst

    Name: Emmanuel Vergeynst

    Title: COMEX Member

       
       
     

    EDMOND DE ROTHSCHILD FUND

     

    By: /s/ Flavien Duval

    Name: Flavien Duval

    Title: Member of the Board

     

    By: /s/ Hervé Touchais

    Name: Hervé Touchais

    Title: Member of the Board

     

     

     

     

    Get the next $PACB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PACB

    DatePrice TargetRatingAnalyst
    11/11/2024Buy → Neutral
    UBS
    6/3/2024$4.00Buy
    Jefferies
    4/22/2024Overweight → Neutral
    JP Morgan
    4/18/2024$7.00 → $2.50Buy → Neutral
    Goldman
    12/14/2023$11.00Overweight
    Stephens
    12/14/2023Neutral
    Guggenheim
    12/13/2023Peer Perform
    Wolfe Research
    11/17/2023$13.00 → $10.00Neutral → Buy
    UBS
    More analyst ratings

    $PACB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Pacific Biosciences downgraded by UBS

      UBS downgraded Pacific Biosciences from Buy to Neutral

      11/11/24 9:44:33 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Jefferies resumed coverage on Pacific Biosciences with a new price target

      Jefferies resumed coverage of Pacific Biosciences with a rating of Buy and set a new price target of $4.00

      6/3/24 8:16:36 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Pacific Biosciences downgraded by JP Morgan

      JP Morgan downgraded Pacific Biosciences from Overweight to Neutral

      4/22/24 7:40:44 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PACB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Gibson James R Ii was granted 1,000,000 shares (SEC Form 4)

      4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

      4/2/25 4:18:38 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 3 filed by new insider Gibson James R Ii

      3 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

      4/2/25 4:09:07 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Officer Farmer Michele was granted 89,835 shares, increasing direct ownership by 49% to 274,454 units (SEC Form 4)

      4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

      3/21/25 4:55:45 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PACB
    Financials

    Live finance-specific insights

    See more
    • PacBio Announces First Quarter 2025 Financial Results

      MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results:  Q1 2025Q1 2024Revenue$37.2 million$38.8 millionInstrument revenue$11.0 million$19.0 millionConsumable revenue$20.1 million$16.0 millionService and other revenue$6.0 million$3.8 millionRevio™ systems1228Vega™ systems28—Annualized Revio pull-through per system~$236,000~$254,000Cash, cash equivalents, and investments$343.1 million$561.9 million Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the correspon

      5/8/25 4:15:34 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million

      Implements Plan to Reduce Annualized Operating Expense Run Rate by $45 Million to $50 Million Q1 2025 Earnings Conference Call Scheduled for May 8, 2025 MENLO PARK, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2025. Preliminary First Quarter Results  Preliminary Q1 2025Q1 2024Revenue$36.9 million$38.8 millionInstrument revenue$10.8 million$19.0 millionConsumable revenue$20.1 million$16.0 millionService and other revenue$6.0 million$3.8 millionRevio systems1228Vega systems28-Annualized Revio pull-through per system~$236,000~$254,000Cash, cash equivalents, and investments$343.1 million$561.9

      4/9/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results

      MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter results Revenue of $39.2 million, a 33% decrease compared with $58.4 million in the prior-year period.Instrument revenue of $15.3 million compared with $35.1 million in the prior-year period. Instrument revenue in the fourth quarter of 2024 included 23 Revio® sequencing systems and 7 Vega™ sequencing systems.Consumables revenue of $18.8 million compared with $18.9 million in the prior-year period.Service and other revenue of $5.1 million compared with $4.4 million in the prior-year period. Gross margin, opera

      2/13/25 4:05:00 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PACB
    Leadership Updates

    Live Leadership Updates

    See more
    • Jim Gibson to join PacBio as Chief Financial Officer

      MENLO PARK, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced Jim Gibson will join and be appointed as the company's new Chief Financial Officer, effective as of his start date, which is expected to be March 31, 2025. With over three decades of financial leadership experience at some of Silicon Valley's most iconic and innovative companies, Mr. Gibson brings a deep track record of operational excellence, strategic financing, and scaling global organizations. Mr. Gibson joins PacBio from Sequoia, a strategic compensation and benefits solutions provider, where he served as CFO across

      3/27/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service

      MENLO PARK, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggiero as the company's new Global Head of Sales & Service. Mr. Ruggiero brings over two decades of experience in sales leadership within the technology and life sciences sectors. Prior to joining PacBio, he served as Senior Vice President, North America for Sinch AB, a leading global provider of cloud-based communication solutions for business and mobile operators. In his role he led North American sales for the enterprise, mid-market segments. Before that, he held senior sales positions at Zoom V

      2/3/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Announces Appointment of Chris Smith to Board of Directors

      MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Chris Smith to its Board of Directors, effective today. Mr. Smith is currently the Chief Executive Officer of NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company. Mr. Smith, a seasoned executive with extensive experience in the life sciences and healthcare industries, brings a strong track record of leadership in genomics, diagnostics, and corporate strategy. As CEO of NeoGenomics, a leading provider of oncology testing services, he has overseen the company's continued growth and in

      1/30/25 9:05:00 AM ET
      $NEO
      $PACB
      Precision Instruments
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PACB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PacBio Announces First Quarter 2025 Financial Results

      MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results:  Q1 2025Q1 2024Revenue$37.2 million$38.8 millionInstrument revenue$11.0 million$19.0 millionConsumable revenue$20.1 million$16.0 millionService and other revenue$6.0 million$3.8 millionRevio™ systems1228Vega™ systems28—Annualized Revio pull-through per system~$236,000~$254,000Cash, cash equivalents, and investments$343.1 million$561.9 million Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the correspon

      5/8/25 4:15:34 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • First Effort to Integrate PacBio HiFi Whole Genome Sequencing in Newborn Screening Launches in Thailand

      MENLO PARK, Calif. and BANGKOK, May 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) a leading provider of high-quality, highly accurate sequencing platforms, and Chulalongkorn University, a national leader in genomic and translational research, today announced a strategic collaboration to implement PacBio HiFi whole genome sequencing (WGS) as part of a newborn screening research program. This marks the first initiative in Asia Pacific to explore the use of PacBio's HiFi sequencing technology at population scale - an effort designed to evaluate how comprehensive genomic data can support earlier, more accurate identification of rare and treatable conditions in newborns. The collaboration h

      5/5/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Announces Plans to Improve Methylation Detection in HiFi Chemistry

      MENLO PARK, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced it plans to improve on its already highly accurate methylation detection capabilities in HiFi chemistry through licensing advanced DNA methylation detection methods developed by Professor Dennis Lo and colleagues at the The Chinese University of Hong Kong (CUHK) and Centre for Novostics. The licensed technology is designed to enhance PacBio HiFi sequencing with improved detection of DNA base modifications—including 5-hydroxymethylcytosine (5hmC) and hemimethylated 5-methylcytosine (5mC)—in native DNA. PacBio plans to bring th

      4/28/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PACB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Pacific Biosciences of California Inc.

      SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      11/26/24 8:27:01 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Pacific Biosciences of California Inc.

      SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      11/14/24 5:52:54 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Pacific Biosciences of California Inc.

      SC 13G/A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      11/14/24 5:48:11 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PACB
    SEC Filings

    See more
    • Pacific Biosciences of California Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

      5/8/25 4:19:09 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by Pacific Biosciences of California Inc.

      SCHEDULE 13G/A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      4/30/25 11:13:15 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEFA14A filed by Pacific Biosciences of California Inc.

      DEFA14A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

      4/23/25 4:41:05 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PACB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Meline David W bought $176,160 worth of shares (40,000 units at $4.40) (SEC Form 4)

      4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

      3/6/24 5:36:07 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials